Our guest speaker, Dr. Jonathan Sackner-Bernstein, is a widely sought expert in medical product development, with expertise from first-in-human to post-market stages with deep understanding of regulatory, clinical, operational, analytic, and due-diligence processes. Recently, Dr. Bernstein has identified a novel candidate drug therapy for Parkinson's disease (patent pending), along with working through regulatory steps required to start a clinical trial.
During this webinar, Dr. Bernstein:
- Defines a new paradigm for Parkinson's disease
- Identifies therapeutic implications of this discovery
- Delineates a path to test this new paradigm, and in parallel, the possibility of modifying the disease
